Particle Therapy 2017

1352-1353 / 2605

Randomized(2)
NCT01141478: Loma Linda
– PBT (15 sessions)+ Sorafenib versus Sorafenib
– Primary endpoint: overall survival
– 6/2017
NCT00857805: Loma Linda
– PBT (15 sessions) versus TACE
– Primary endpoint: overall survival
– 1/2018
Source: ClinicalTrials.gov